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esponsibility of InstAbstract An excessive accumulation of extracellular matrix composed by insoluble collagen is the core
pathogenic change of ﬁbroproliferative diseases including pulmonary ﬁbrosis. We recently found that
autophagy, a self-catabolic process that maintains intracellular homeostasis, participates critically in the
regulation of collagen degradation in the ﬁbrotic tissues. Here we report that treatment of mice with
SB216763, a potent and selective inhibitor of glycogen synthase kinase-3 (GSK3), signiﬁcantly decreased
the bleomycin (BLM)-induced acute inﬂammation, attenuated pulmonary ﬁbrosis, improved the lung
function and increased animal survival through activating autophagy. Indeed, we found that treatment of
mice or cultured cells with SB216763 restored the autophagy in vivo and in vitro through increasing the
expression of autophagy related proteins and decreasing the physical interaction of Bcl-2 and Beclin-1.
Additionally, SB216763 stimulated the binding of Bcl-2 and GSK3, which reduces the interaction of Bcl-
2 and Beclin-1. We conclude that the GSK3 inhibitor SB216763 improves the BLM-induced pulmonary
ﬁbrosis through stimulating autophagy core complex to restore the activity of autophagy in ﬁbrotic lung
tissue. Our work suggests that using a moderate autophagic agonist, such as SB216763, is a promisingdica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and hosting by
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SB216763 inhibits pulmonary ﬁbrosis via stimulating autophagy 227therapeutic strategy for the treatment of devastating ﬁbroproliferative diseases such as idiopathic
pulmonary ﬁbrosis.
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Tissue ﬁbrosis is a core structure change and underling mechanism
for a variety of incurable chronic lung diseases. It is characterized by
an excessive accumulation of extracellular matrix (ECM) leading to
stiffening and/or scarring of the involved tissue, which destructs the
normal lung architecture, affects lung functions, and causes failure of
lung organ1,2. Because no convincing or effective therapeutics are
available for the treatment of pulmonary ﬁbrosis, it has a mortality
rate that exceeds that of many cancers3. The parenchymal collagen,
the major insoluble ﬁbrous protein, is the main substance of the
ECM, and is deposited in the ﬁbrotic lung disease4. There are various
signal pathways that regulate the expression of collagen and induce
the development of pulmonary ﬁbrosis, including stimulating the
transforming growth factor 1 (TGF-1) signal pathway5. Moreover, the
attenuation of collagen degradation is also observed increasingly in
the pulmonary ﬁbrosis6,7.
Autophagy, a self-catabolic process that maintains intracellular
homeostasis and determines cell fates under stress, has been recently
found to degrade the collagen and resolute the pulmonary ﬁbrosis in
tissue repairing process6,7. Indeed, autophagy has been recognized
as a key mechanism for cellular homeostasis and survival in a
variety of lung diseases8. The autophagy core complex, comprised
of Bcl-2, Beclin-1, Vps34, Vps15, Atg14, and Ambra1, plays a
crucial role in autophagy activation process9. Bcl-2 binds to Beclin-
1 by BH3 domain to protect the activation of autophagy under
quiescent conditions. When cells are stimulated by a variety of
stimuli, Bcl-2 is isolated from Beclin-1 and the autophagic activity
is enhanced in the cells9. Therefore, the integration of Bcl-2 and
Beclin-1 is a switcher of autophagy activation.
Glycogen synthase kinase-3 (GSK3) is a serine-threonine kinase,
and it is involved in energy metabolism, neuronal cell development,
and body pattern formation. GSK3 regulates these cellular activities
through regulating the integration of signaling or functional proteins.
GSK3 binds to tau and phosphorylates it to regulate negatively its
ability of stabilizing microtubule structure10. And GSK3 promotes the
expression of p53, a tumor suppressor gene, through binding to p53,
and induces the cell apoptosis in the mitochondria11. Moreover, GSK3
up-regulates the activity of autophagy through integrating acetyltrans-
ferase TIP60 and stimulating the protein kinase ULK1, which is
required for activating autophagy12. And our previous work reported
that SB216763, the potent and selective GSK3 inhibitor, increases the
expression of Bcl-213. It suggests that SB216763 may affect the
activity of autophagy by regulating the integration of Bcl-2 and Beclin-
1, which may be due to its capacity of inhibiting GSK3. Thus
SB216763 may attenuate the pulmonary ﬁbrosis through regaining the
activity of autophagy.
In this study, we document that the GSK3 inhibitor SB216763
attenuates tissue injury, inﬂammation, pulmonary ﬁbrosis, and
lung dysfunction by restoring the autophagic activity in acutely
injured lungs. Treatment of mice with SB216763 activates the
autophagic core complex and promotes the degradation of collagen
in the BLM-induced ﬁbrotic lungs through interrupting the Bcl-2and Beclin-1 interaction. SB216763 attenuates the activity of
GSK3 and enhances the integration of GSK3 and Bcl-2, which
restrains the binding of Bcl-2 and Beclin-1. Our studies suggest
that using a moderate autophagic agonists such as GSK3 inhibitor,
is a promising therapeutic strategy for the treatment of ﬁbropro-
liferative diseases such as idiopathic pulmonary ﬁbrosis.2. Materials and methods
2.1. Reagents
BLM was purchased from Nippon Kayaku (Tokyo, Japan). SB216763
was obtained from Sigma (St. Louis, MO). Alexa Fluor 488 and 647
Abs were obtained from Invitrogen. Mouse IgG and anti-mouse Bcl-2,
Beclin-1, Vps34, p-Bcl-2 (S70), p62, Light chain 3 (LC3) II/I,
lysosome-associated membrane protein 1 (LAMP-1), and β-actin
antibodies were obtained from Cell Signaling Technology (Danvers,
MA). Other materials were purchased from commercial sources.
2.2. Preparation of pulmonary ﬁbrosis
Male C57BL/6J mice (1771 g, 6–8 weeks) were obtained from
Vital River Laboratory Animal Technology. The mice were anesthe-
tized with 50 mg/kg pentobarbital ip (Merck). Using an insulin
syringe, 50 mL of LPS-free saline, clinical grade BLM (3.0 U/kg)
was injected directly into the trachea as previously described14. The
SB216763 (20 mg/kg)15 was injected ip in saline on day 14, 17, and
21 after BLM instillation. Mice were sacriﬁced by excessive doses of
anesthesia for the lungs on day 28 after BLM instillation. The lungs
were excised and were ﬁxed or frozen for morphological evaluation
or measurement of hydroxyproline content.
All animal protocols were conformed to the Guidelines for the
Care and Use of Laboratory Animals prepared and approved by
the Animal Care and Use Committee of the Chinese Academy of
Medical Sciences and Peking Union Medical College.
2.3. Lung functions measurement
Twenty eight days after bleomycin injured, mice were anesthetized
with 50 mg/kg ip pentobarbital and placed on ﬂexivent system
(ﬂexiVent, SCIREQ Inc., Montreal, Canada). Mice were mechani-
cally ventilated with tidal volume 10 mL/kg and respiratory rate of
150 breaths/min. Lung function parameters were calculated by the
measurements of total lung capacity (deep inﬂation of the mice
lungs to a pressure of 30 cm H2O followed by a breath hold for a
few seconds), Snapshot (single-frequency forced oscillation wave-
form with the frequency at 150 breaths/min), Quickprime-3 (multi-
frequency forced oscillation waveforms), and pressure–volume
loops (slow stepwise inﬂation to TLC and deﬂation back to FRC).
All perturbations were performed until three acceptable measure-
ments with coefﬁcient of determination (COD) ≥0.9 were recorded
in each individual subject.
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The lungs were rapidly excised, ﬁxed with 4% paraformaldehyde, and
embedded in parafﬁn for histopathological examination as previously
described14. Lung tissue sections (5 mm thick) were prepared and
stained with H&E, or Masson's trichrome. The grade of pulmonary
inﬂammation and ﬁbrosis was blindly assessed by a professional
pathologist. The average integrated OD (IOD) of collagen deposition
from 10 randomly chosen regions per tissue sample at a magniﬁcation
of 200 was determined using Image-Pro Plus image analysis
software (Media Cybernetics, Silver Spring, MD).
2.5. Measurement of lung hydroxyproline
Collagen deposition was determined by measuring the total hydro-
xyproline content of the lungs according to the revised Reddy GK
method14. In brief, the lungs were hydrolyzed with 2.5 M NaOH at
120 1C, 0.1 kPa for 40 min. After neutralization with hydrochloric
acid, the hydrolyzation products were diluted with distilled water. The
hydroxyproline content of the hydrolyzation products was assessed
calorimetrically at 550 nm with p-dimethylaminobenzaldehyde. The
results were represented as micrograms per lung.
2.6. Plasmids construction
Mouse GSK3 was generated by PCR with appropriate primer
plasmids and subcloned in frame to the pcDNA6-HA expression
plasmid. Mouse Beclin-1 was generated by PCR and subcloned in
frame to the pFLAG-CMV-2 expression plasmid. Myc-tagged Bcl-
2 plasmid was a gift from Dr. W. Stratford May, Jr. (University of
Florida Shands Cancer Center).
2.7. Cell culture
The mouse type II alveolar epithelial cells (MLE-12) were cultured
in DMEM-Ham's Nutrient Mixture F12 (1:1; Hyclone) supple-
mented with 2% FBS and L-glutamine (full-nutrient medium). The
cells were passaged every 2 days.
2.8. Semi-quantitative RT-PCR
The expression of Bcl-2 mRNA was analyzed as described
previously16. Total RNA was isolated from MLE-12 cells using
the TRIzol kit (Invitrogen) according to the manufacturer's
instructions. Next, the RNA was reverse-transcribed and ampliﬁed.
PCR was performed using a Mycycler thermal cycler, and the
ampliﬁed products were analyzed by agarose gel. The following
speciﬁc primer sequences were used: 5′-ACGGCTGCACGAGT-
CACAC–3′ and 5′-GGCAGGCGGGAGGTCTT-3′ (mouse col-
lagen I); and 5′-TAACCAACTGGGACGATATG-3′ and 5′-
AAACAGGGACAGCACAGCCT-3′ (mouse β-actin). All values
obtained were normalized to the values obtained for β-actin.
2.9. Immunoprecipitation and Western blotting
Cells were washed three times with phosphate-buffered saline,
harvested, and lysed in co-immunoprecipitation buffer that has
been described before17. Total cell lysates (5 mg protein) were
subjected to immunoprecipitation with appropriate antibodies, as
indicated, overnight at 4 1C with gentle agitation, followed by
incubation with protein A/G Plus-agarose for 24 h at 4 1C. Theimmunocomplex was washed three times and then mixed with 2
SDS sample buffer and boiled for 5 min. For Western blotting, co-
precipitates or whole cell extracts were resolved by SDS-PAGE
and blotted on PVDF membranes (Millipore). The membranes
were immunoblotted with the indicated antibodies and developed
using an ECL detection system (Amersham Bioscience).
2.10. Confocal assay
Standard protocols for immunoﬂuorescence microscopy were used as
described previously17. The lung tissue (0.5 μm thick) on the glass
slide was prepared and stained with indicated primary Abs overnight
at 4 1C. The sections were washed twice, incubated with
ﬂuorochrome-labeled secondary Abs (1:200) for 30 min, and washed
three times after staining. Images were obtained with a Leica SP2
confocal microscope and analyzed with Leica confocal software.
2.11. Statistics
Data are represented as the mean7SE. Statistical analyses were
performed using Student's t-test for two-group comparisons.
The survival rates were analyzed using the Kaplan–Meier method.
The P value was set at 0.05. All statistics were analyzed using
SPSS 17.0 software.3. Results
3.1. SB216763 attenuates BLM-induced pulmonary ﬁbrosis
through accelerating the degradation of collagen
We recently reported that IL-17A inhibits the GSK3-induced
degradation of Bcl-2 and promotes the expression of Bcl-2 to
attenuate the activity of autophagy13. Moreover, blockade of IL-
17A activity restores the autophagic ﬂux to suppress pulmonary
ﬁbrotic after BLM challenged7. And SB216763, the GSK3
inhibitor, also revealed the capacity of suspending Bcl-2 degrada-
tion13. Hence, we further determined the regulatory effect of
SB216763 in BLM-induced pulmonary ﬁbrotic. However, we
found that SB216763 reversed BLM-established pulmonary ﬁbro-
sis, as demonstrated by the reduced acute inﬂammation, deposition
of collagen (Fig. 1A and B) and the hydroxyproline content
(Fig. 1C) in the damaged lung. These factors also contributed to
the increased survival of BLM challenged mice (Fig. 1D). But
SB216763 did not reduce the collagen mRNA expression after
BLM challenged (Fig. 1E). These data suggest that SB216763
reduces the deposition of collagen in the BLM treatment lung
through accelerating the degradation of collagen.
3.2. SB216763 reverses the BLM-induced reduction
in pulmonary function
Subsequently, we investigated the physiological function of the lung
tissue through detecting the pulmonary function in the BLM
treatment mouse. We found that SB216763 increased inspiratory
capacity (IC), compliance of the respiratory system (Crs) and static
compliance (Cst) after BLM-challenged (Fig. 2A, D and E). More-
over, SB216763 decreased the respiratory resistance (Rrs), elastic
resistance (Ers) and static elastance (Est) while the BLM increased
them (Fig. 2B, C and F). These data indicate that SB216763 reverses
the BLM-induced reduction in pulmonary function.
Figure 2 SB216763 reverses the BLM-induced reduction in pulmonary function. (A–F) The parameters of lung function. SB216763 signiﬁcantly
reduces the BLM-induced IC, Rrs, Ers, Crs, Cst, and Est. Data were presented as mean7SE (n¼5/group/experiment). *Po0.05; **Po0.01.
Figure 1 SB216763 attenuates BLM-induced pulmonary ﬁbrosis through accelerating the degradation of collagen. (A–C) SB216763 promotes
the resolution of the BLM-induced pulmonary inﬂammation and ﬁbrosis as indicated by Masson's trichrome staining of lung sections (A), H&E
staining of the lung sections (B) and hydroxyproline content (C), scale bar: 75 μm. Data are represented as the mean7SE (n¼7/group/
experiment). (D) SB216763 treatment increased the survival rates of BLM-treated mice. (E) SB216763 treatment does not affect the mRNA of
collagen after BLM challenge. Data are presented as the mean7SE of four independent assays. *Po0.05; **Po0.01; N.S., non-signiﬁcant.
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attenuating the interaction of Bcl-2 and Beclin-1
Autophagy, a self-catabolic process that maintains intracellular home-
ostasis and determines cell fates under stress, has been recently found
to be involved in the regulation of tissue repairing process and ﬁbrosis6.
Our previous work pointed out that neutralizing IL-17A, a negative
regulator of autophagy, promotes the degradation of collagen through
activation of autophagy7. We therefore examined if SB216763
augments the activity of autophagy to degrade collagen in the MLE-
12 cells. We found that SB216763 increased the ratio of LC3-II/LC3-I
and p-Bcl-2/Bcl-2, and increased the expression of Beclin-1 and Vps34
in the lung epithelial cells (Fig. 3A). Because Bcl-2 binds to Beclin-1,
the key component of autophagy core complex, to inhibit the activity
of autophagy, we further determined the regulatory effect of SB216763Figure 3 SB216763 stimulates the activity of autophagy through attenuat
expression of autophagy-associated proteins. (B) SB216763 reduces the int
of GSK3 and Bcl-2. (D) SB216763 does not attenuate phosphorylation of JN
four independent assays. *Po0.05; **Po0.01; ***Po0.001; N.S., non-son the interaction of Bcl-2 and Beclin-1. The immunoprecitation assay
revealed that stimulation of lung epithelial cells with SB216763
reduced the integration of Bcl-2 and Beclin-1 (Fig. 3B). At the
meanwhile, SB216763 increased the integration of Bcl-2 and GSK3
(Fig. 3C). However, SB216763 did not effect the activity of JNK-1, a
stimulator of autophagy through weakening the interaction of Bcl-2
and Beclin-1 (Fig. 3D). These data indicate that SB216763 can
stimulate the activity of autophagy through attenuating the interaction
of Bcl-2 and Beclin-1.
3.4. SB216763 restores autophagic activity in the lung tissue
of BLM-treated mouse
Subsequently, we examined the regulatory effect of SB216763 on
the activity of autophagy in the BLM treatment lung. We founding the integration of Bcl-2 and Beclin-1. (A) SB216763 enhances the
egration of Beclin-1 and Bcl-2. (C) SB216763 enhances the integration
K-1 when the cells are starved. Data are presented as the mean7SE of
igniﬁcant.
Figure 4 SB216763 restores autophagic activity in the lung tissue of BLM-treated mouse. (A) SB216763 enhances the expression of autophagy-
associated proteins in the lung of BLM-treated mouse. (B) SB216763 enhances the numbers of autophagolysosomes in the lung. The
autophagolysosomes were evaluated by the co-expression of LC3 and LAMP-1 staining, green for LC3 and red for LAMP-1, scale bar: 7.5 μm.
The images are representatives of three independent experiments (n¼6/group/experiment). (C) SB216763 reduces the integration of Beclin-1 and
Bcl-2 in the BLM-treated mouse. Data are presented as the mean7SE of four independent assays. (D) Schematic diagram of the mechanism of
SB216763-mediated attenuation of pulmonary ﬁbrosis. *Po0.05; **Po0.01; ***Po0.001; N.S., non-signiﬁcant.
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indicated by the increased ratio of LC3-II/LC3-I in ﬁbrotic tissues
(Fig. 4A). Moreover, SB216763 further decreased the expression
of p62 in ﬁbrotic tissues (Fig. 4A). We subsequently examined the
expression of Beclin-1, Vps34, and the ratio of p-Bcl-2/Bcl-2,
because the autophagic core complex regulates the activity of
autophagy and is required for autophagosome formation in the
autophagy process18. The expression of Beclin-1 was increased,
but the expression of Vps34 and the ratio of p-Bcl-2/Bcl-2 were
decreased in the ﬁbrotic lung tissues from the BLM-treated mice.
However, the expression of Beclin-1 and Vps34, as well as the
ratio of p-Bcl-2/Bcl-2, was increased in the ﬁbrotic lung tissues
from the SB216763-treated animals (Fig. 4A). And SB216763
enhanced the co-expression of lysosome-associated membraneprotein 1 (LAMP-1) and the autolysosomal maker LC319 in
ﬁbrotic lung tissues (Fig. 4B), which indicated that SB216763
promoted the formation of autolysosomes. Moreover, the immu-
noprecitation assay revealed that the treatment of SB216763
reduced the integration of Bcl-2 and Beclin-1 (Fig. 4C). Taken
together, these data indicate that SB216763 can induce an effectual
autophagy in the ﬁbrotic lung tissue.4. Discussion
SB216763 has been found in the regulation of tumorigenesis and
neurodegenerative disease because of the potent function about
selective inhibiting glycogen synthase kinase-3. It is reported that
H. Liu et al.232the activity of GSK3 is hyperactive in the patients with osteo-
sarcoma specimens and suppression of GSK3 by SB216763
resulted in apoptosis of osteosarcoma cells20. SB216763 could
reverse the hippocampus-dependent learning deﬁcits and rescue
adult hippocampal neurogenesis at multiple stages in Fmr1 KO
mice through inhibiting the activity of GSK321. However, the
exact relationship of SB216763 and ﬁbroproliferative diseases is
rarely reported, except that Gurrieri et al.15 pointed out that
SB216763 prevented lung inﬂammation and the subsequent
ﬁbrosis when co-administered with BLM. But they neither detect
the changes of pulmonary function after SB216763 treatment nor
involve the SB216763 regulatory effect on autophagy in the lung
ﬁbrosis.
A number of studies have demonstrated that the activity of
autophagy attenuates the development and progression of pulmon-
ary ﬁbrosis through stimulating the collagen degradation6,7. And
Kim et al.22 also indicated that the autophagy promotes intracel-
lular degradation of type I collagen induced by TGF-1 in the
kidney ﬁbrosis. Our current studies indicate that SB216763
stimulates the autophagy in vivo and in vitro through regulating
the expression of autophagy relate proteins (such as Bcl-2, p-Bcl-
2, Beclin-1, Vps34, LC3, and p62) and the integration of Bcl-2
and Beclin-1 (Figs. 3 and 4). This ﬁnding is consistent with that
SB216763 promotes the expression of LC3-II and aggregation of
punctate dots containing LC3 when the rats are attacked by
ischemic brain injury23. However, SB216763 increases the protein
level of Atg5 and mTOR and decreases the activity of autophagy
in the chronic myeloid leukemia cells with imatinib mesylate
resistance24, which suggested that inhibiting GSK3 by SB216763,
which induces a state of the growth factor deprivation, has
different regulatory effects on the activation of autophagy in the
ﬁbrosis and tumorigenesis.
The autophagy core complex plays a crucial role in autophagy
activation process9. Bcl-2 binds to Beclin-1 by BH3 domain to
protect the activation of autophagy under quiescent conditions.
Our previous studies indicate that IL-17A–PI3K–GSK3–Bcl-2
signaling pathway participates in the attenuation of autophagic
activity in lung epithelial cells13. Indeed, we found the GSK3
inhibitor SB216763 increased the integration of GSK3 and Bcl-2
and decreased the integration of Beclin-1 and Bcl-2 (Fig. 3B and
C), which means that the SB216763 stimulated the autophagy
through attenuation of the integration of Beclin-1 and Bcl-2. Wei
and his colleagues found that JNK1 promotes Bcl-2 dissociation
from Beclin-1 and autophagy activation through phosphorylating
Bcl-225. However, we found SB216763 did not stimulate JNK1 in
the MLE-12 cells at the present work (Fig. 3D). In spite of this
observation, we did not deny that SB216763 may activate
autophagy through regulating the activity of some protein kinases,
because selectivity of SB216763 is not enough special like
knockdown of gene.5. Conclusions
In summary, our current study shows that SB216763, a GSK3
inhibitor, attenuates BLM-induced lung ﬁbrosis through augment-
ing the Bcl-2 dissociation from Beclin-1 and activating autophagy
subsequently (Fig. 4D). SB216763 inhibits the integration of Bcl-2
and Beclin-1 while it aggregates the binding of Bcl-2 and GSK3.
The free Beclin-1 stimulates the autophagy core complex and
autophagy, the primary pathway for degradation of collagen and
the clearance of injured tissue debris. Our ﬁndings revealed anovel molecular mechanism of SB216763 in the regulation of
autophagy in lung epithelial cells and lung ﬁbrosis tissue. Our
work indicates that blocking GSK3 activity to stimulate autophagy
is a promising therapeutic strategy for the prevention and treatment
of ﬁbroproliferative diseases such as pulmonary ﬁbrosis.Acknowledgments
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